Combined Use of Warfarin and Oral P2Y12 Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome

ConclusionsAmong Medicare beneficiaries with AF and ACS, combination therapy with warfarin and P2Y12 inhibitor was uncommon during the 90‐day ascertainment period, and more than one‐quarter of patients had no claims for warfarin or P2Y12 inhibitors. Rates of all‐cause readmission and mortality within 1 year of hospitalization for ACS were high.

Source: Clinical Cardiology - December 1, 2013 Category: Cardiology Authors: W. Schuyler Jones, Xiaojuan Mi, Manesh R. Patel, Roger Mills, Adrian F. Hernandez, Lesley H. Curtis Tags: Clinical Investigation Source Type: research